TY - JOUR
T1 - siRNA intervention inhibiting viral replication and delivery strategies for treating herpes simplex viral infection
AU - Manda, Vyshnavi
AU - Josyula, Venkata Rao
AU - Hariharapura, Raghu Chandrashekar
N1 - Publisher Copyright:
© 2019, Indian Virological Society.
PY - 2019/6/1
Y1 - 2019/6/1
N2 - The effective treatment of herpes simplex virus (HSV) infections generally involves the use of antiviral nucleoside drugs, but with increasing reports of antiviral resistance, the use of these drugs is challenged. Hence, a need arises to explore alternate treatment options. In this review we have discussed various targets that have been explored to control the HSV replication using siRNA therapeutics. We have also discussed the advantages of targeting a less explored UL10 gene to develop an alternate therapeutic intervention. Gene silencing can induce an inhibitory activity to virus spread and infection. The capacity and suitability of UL10 gene as siRNA induced silencing target in eliciting the desired antiviral effect in patients is identified and particularly discussed. The major challenge associated with the siRNA therapeutics is their delivery. The various viable delivery options, that are being explored in the recent times is summarized and different delivery pathways and strategies are reviewed as a part of the study.
AB - The effective treatment of herpes simplex virus (HSV) infections generally involves the use of antiviral nucleoside drugs, but with increasing reports of antiviral resistance, the use of these drugs is challenged. Hence, a need arises to explore alternate treatment options. In this review we have discussed various targets that have been explored to control the HSV replication using siRNA therapeutics. We have also discussed the advantages of targeting a less explored UL10 gene to develop an alternate therapeutic intervention. Gene silencing can induce an inhibitory activity to virus spread and infection. The capacity and suitability of UL10 gene as siRNA induced silencing target in eliciting the desired antiviral effect in patients is identified and particularly discussed. The major challenge associated with the siRNA therapeutics is their delivery. The various viable delivery options, that are being explored in the recent times is summarized and different delivery pathways and strategies are reviewed as a part of the study.
UR - http://www.scopus.com/inward/record.url?scp=85060621563&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060621563&partnerID=8YFLogxK
U2 - 10.1007/s13337-018-00508-z
DO - 10.1007/s13337-018-00508-z
M3 - Comment/debate
AN - SCOPUS:85060621563
SN - 2347-3584
VL - 30
SP - 180
EP - 185
JO - VirusDisease
JF - VirusDisease
IS - 2
ER -